Research Database
Evidence-based research profiles. Not medical advice.
66 peptides
Body Protection Compound 157
BPC-157 is a synthetic peptide whose promoted regenerative effects come almost entirely from animal and laboratory research. Reliable human efficacy and safety data are lacking.
Thymosin-β4 fragment (17–23)
TB-500 is a commercially marketed synthetic fragment of thymosin beta-4. Studies of full-length thymosin beta-4 do not prove efficacy or dosing for TB-500.
Growth hormone secretagogue
Ipamorelin is an experimental growth-hormone secretagogue. Small early human studies show a GH response but do not establish long-term health benefit.
Long-acting growth hormone-releasing hormone analog with DAC
CJC-1295 DAC is a long-acting experimental GHRH analogue. Early studies show sustained increases in GH and IGF-1, but it is not an approved therapy and long-term benefit is unproven.
Growth Hormone Releasing Peptide-2
GHRP-2 stimulates growth-hormone release. Human experiments studied hormone responses and appetite; they do not establish benefits for muscle gain or anti-aging.
GHRH(1–29)-NH₂
Sermorelin is a short GHRH analogue that stimulates growth hormone. It has a historical US approval as Geref; this does not validate anti-aging use of current compounded products.
Semaglutide · GLP-1 receptor agonist
Semaglutide is a GLP-1 receptor agonist used in approved medicines. Indication, formulation and dosing depend on the specific product.
Tirzepatide · GIP/GLP-1 receptor agonist
Tirzepatide activates GIP and GLP-1 receptors. Approved products have their own indications and administration requirements.
Tuftsin analogue
Selank is a synthetic peptide with limited clinical research into anxiety symptoms. Current evidence does not reliably establish broad benefit or long-term safety.
Epitalon · Ala-Glu-Asp-Gly
Epithalon is an experimental tetrapeptide studied in aging research. Cell findings do not demonstrate lifespan extension or rejuvenation in humans.
Glycyl-L-histidyl-L-lysine copper complex
GHK-Cu is a copper-tripeptide complex studied in cell models of collagen production. Cosmetic use and systemic injection have different evidence and risk profiles.
Adipotide is an experimental peptide conjugate targeting the blood supply of fat tissue. Its evidence is primarily preclinical primate research.
AOD-9604 is an experimental growth-hormone fragment. Clinical obesity research did not establish weight loss, and AOD-9604 is not an approved weight-loss medicine.
Cagrilintide is a long-acting amylin analogue studied in obesity.
Retatrutide is a triple receptor agonist in clinical development and is not an approved medicine.
Mazdutide is a dual GLP-1/glucagon receptor agonist. It was approved in China in 2025 for weight management and type 2 diabetes; it does not have corresponding EU or US approval.
Survodutide is investigated clinically as a dual glucagon/GLP-1 receptor agonist.
MOTS-c is a mitochondrially encoded peptide studied in experimental metabolism research.
Glutathione · GSH
Glutathione is an endogenous tripeptide involved in redox balance. An oral human trial measured changes in glutathione stores.
Tesamorelin is a GHRH analogue. In the US, EGRIFTA WR is approved for excess abdominal fat in adults with HIV-associated lipodystrophy.
Bremelanotide
PT-141 is bremelanotide. VYLEESI has US approval for acquired, generalized HSDD in premenopausal women.
Somatropin
HGH 191AA denotes the 191-amino-acid human growth hormone. Somatropin medicines have defined medical indications.
Human chorionic gonadotropin
hCG is a glycoprotein hormone. Medicines such as PREGNYL are used in selected endocrine and reproductive settings.
Menotropins
hMG is not one short peptide but a gonadotropin preparation with FSH and LH activity.
Oxytocin is a peptide hormone used medically in obstetrics, distinct from wellness or bonding claims.
GnRH
Gonadorelin corresponds to GnRH, the releasing hormone for LH and FSH. LHRH Ferring is an approved gonadorelin diagnostic medicine in Germany.
Kisspeptins are related peptides involved in reproductive regulation. Kisspeptin-10 and -54 are different molecular forms.
GHRP-6 is a synthetic growth hormone-releasing peptide with early human research.
Modified GRF terminology
“CJC-1295 NO DAC” is a market term that must be distinguished from CJC-1295 with DAC.
Cibinetide
ARA-290/cibinetide is an investigational peptide studied in small trials of sarcoidosis-associated small-fiber loss; no approval is established.
Cerebrolysin is a complex peptide/amino-acid mixture. Individual studies report positive functional endpoints, but the current Cochrane synthesis found no demonstrated mortality benefit.
Delta sleep-inducing peptide (emideltide)
DSIP/emideltide is an experimental peptide with very small, old sleep studies. In 2026 the FDA separately evaluated the free base and acetate for proposed compounding uses.
ACTH(4–7)-Pro-Gly-Pro
Semax is an ACTH-related investigational peptide. The captured human report concerns stroke rehabilitation; it demonstrates neither enhancement in healthy people nor effects of N-acetylated variants.
PE-22-28 is a shortened spadin analogue from preclinical TREK-1 research.
Glu-Asp-Arg (EDR)
Pinealon is a synthetic tripeptide studied in cellular oxidative-stress models.
FOXO4-DRI is an experimental senolytic peptide approach studied in cells and mice, not a clinically established anti-aging therapy.
Long R3 insulin-like growth factor I
IGF-1 LR3 is a modified IGF-I analogue used experimentally. The captured source is a cell study, not treatment in people.
Lys-Pro-Val
KPV is a tripeptide with cell and mouse data in experimental intestinal inflammation; FDA identified no clinical human-exposure data.
Human cathelicidin antimicrobial peptide LL-37
LL-37 is an antimicrobial peptide. A randomized trial examined only topical use for hard-to-heal venous leg ulcers.
Melanotan II is not approved as a tanning product. The early human evidence is extremely small; regulators warn about products that have not been assessed and serious safety reports.
Mechano-growth factor
MGF is an inconsistent term for an IGF-1 splice variant or a synthetic fragment derived from it; the two are not interchangeable.
PEG-MGF is an unresolved catalogue name for a purportedly PEGylated MGF product; no specific chemical form or clinical evidence is established.
PNC-27 is an experimental peptide in basic cancer research, not an established cancer treatment.
Acetyl octapeptide-3
SNAP-8 is a cosmetic peptide. The captured human study concerns a topical multi-ingredient serum, not isolated SNAP-8.
Elamipretide
In 2025 elamipretide received accelerated US approval as FORZINITY to improve muscle strength in patients with Barth syndrome weighing at least 30 kg.
Thymalfasin
Thymosin alpha-1 is an immunomodulatory peptide studied in specific disease settings. A generic “immune boost” is not established.
Glu-Asp-Gly (EDG)
Chonluten is a short synthetic tripeptide with experimental cell-culture data.
Ala-Glu-Asp-Pro (AEDP)
Cortagen is a synthetic tetrapeptide with animal and ex-vivo cell research; neurological benefit in humans is not established.
Lys-Glu-Asp-Pro (KEDP)
Prostamax appears in an experimental ex-vivo peptide study; no clinical prostate treatment was studied.
Lys-Glu-Asp-Ala (KEDA)
Livagen is a synthetic tetrapeptide with ex-vivo and in-vitro findings; clinical liver or anti-aging benefit is not established.
Lys-Glu (KE)
Vilon is a synthetic dipeptide with laboratory findings on chromatin and inflammatory signaling, not established lifespan extension.
Lys-Glu-Asp-Gly (KEDG)
Testagen is a synthetic tetrapeptide with laboratory findings on uptake of labeled peptides and nucleic-acid interactions.
Lys-Glu-Asp (KED)
Vesugen is a synthetic tripeptide with experimental findings in cell cultures.
Adamax is an unresolved catalogue name. This profile confirms neither molecular or product identity nor any medical effect.
Cartalax is an unresolved catalogue name. This profile confirms neither molecular or product identity nor any medical effect.
Ovagen is an unresolved catalogue name. This profile confirms neither molecular or product identity nor any medical effect.
Three-component mixture from the reference catalogue. The product name does not unambiguously specify the CJC variant.
Catalogue mixture of two research peptides. Different vial strengths are grouped into one profile here.
This drug combination is being studied clinically. An arbitrary catalogue blend is not automatically the CagriSema trial product.
Catalogue mixture of CJC-1295 and GHRP-2. Without explicit product identification, no DAC variant is assigned to CJC here.
This catalogue mixture explicitly names CJC without DAC. It is distinct from combinations containing the DAC form.
GLOW is a blend trade name. The reference catalogue lists GHK-Cu, BPC-157 and TB-500 as its components.
In the reference catalogue, KLOW denotes a mixture of GHK-Cu, BPC-157, TB-500 and KPV.
Neuroxelin is a non-standardized blend name. The captured description names two peptides and two N-acetylated variants; those variants are not equivalent to unmodified Semax or Selank.
Catalogue mixture of tesamorelin and ipamorelin. Approval of a tesamorelin medicine does not approve this blend.
Tri-Heal is a catalogue name for a mixture of TB-500, BPC-157 and KPV. The name is not evidence of healing.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.